MedinCell and the European Investment Bank (EIB) have replaced a financial covenant of their ongoing loan agreement to better fit with MedinCell business model
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
August 31, 2023
August 31, 2023
Participation terms in the Combined General Meeting
August 21, 2023
August 21, 2023
MedinCell’s partner Teva announces successful launch of UZEDY™
August 2, 2023
August 2, 2023
MedinCell has received the last tranche of €10m from the European Investment Bank (EIB) loan
July 31, 2023
July 31, 2023
MedinCell announces its full year financial results April 2022 – March 2023
June 26, 2023
June 26, 2023
MedinCell will publish its annual results (April 2022-March 2023) on June 26, 2023
